Emerging strategies for ErbB ligand-based targeted therapy for cancer

Anticancer Research

Volumn 30, Issue 8, 2010, Pages 3107-3112

  Tsujioka, Hiroshi ^a   Yotsumoto, Fusanori ^a   Shirota, Kyoko ^a   Horiuchi, Shinji ^a   Yoshizato, Toshiyuki ^a   Kuroki, Masahide ^a   Miyamoto, Shingo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cancer; HB EGF; Review; Targeted therapy

Indexed keywords

CETUXIMAB; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER THERAPY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; LUNG CANCER; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR RESISTANCE; DRUG EFFECT; DRUG RESISTANCE; NEOPLASM;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; NEOPLASMS; RECEPTOR, ERBB-2;

EID: 77957373100     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
2. Salomon DS, Brandt R, Ciardiello F and Normando N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995.
3. Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
4. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ and Lemmon MA: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517, 2003.
5. Cho HS and Leahy DJ: Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297: 1330-1333, 2002.
6. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Thomas PJ, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW and Yokoyama S: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541-552, 2003. (Pubitemid 37222478)
7. Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475, 2009.
8. Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
9. Berger MB, Mendrola JM and Lemmon MA: ErbB3/Her3 does not homodimerize upon neuregulin binding at the cell surface. FEBS lett 569: 332-336, 2004.
10. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
11. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN and Yu D: ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 66: 2028-2037, 2006. (Pubitemid 43294911)
12. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
13. Imai K and Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727, 2006. (Pubitemid 44286003)
14. Wang Q and Greene MI: Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest 118: 2389-2392, 2008.
15. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL an Engelman JA: Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. Clin Invest 118: 2609-2619, 2008.
16. Klein S and Levitzki A: Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 21: 185-193, 2009.
17. Miyamoto S, Yagi H, Yotsumoto F, Kawarabayashi T and Mekada E: Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci 97: 341-347, 2006.
18. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E and Miyamoto S: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561, 2009.
19. Higashiyama S and Nanba D: ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 1751: 110-117, 2005. (Pubitemid 41033299)
20. Higashiyama S, Abraham JA, Miller J, Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991.
21. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umeta T, Miyado K, Tamai Y, Kurisaki T, Sehara-Fujisawa A, Ohno S and Mekada E: A metalloprotease- disintegrin MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 17: 7260-7272, 1998.
22. Seals DF and Coutneidges SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 17: 7-30, 1998.
23. Prenzel N, Zwick E, Daub H, Laserer M, Abraham R, Wallasch C and Ullrich A: EGF receptor transactivation by G-protein-coupled receptor requires metalloproteases cleavage of proHB-EGF. Nature 402: 884-888, 1999. (Pubitemid 129515992)
24. Takenobu H, Yamazaki A, Hirata M, Umeta T and Mekada E: The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades. J Biol Chem 278: 17255-17262, 2003.
25. Nanba D, Mammoto A, Hashimoto K and Higashiyama S: Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502, 2003.
26. Kinugasa Y, Hieda M, Hori M and Higashiyama S: The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 282: 14797-14806, 2007. (Pubitemid 47093367)
27. Lin J, Hutchinson L, Gaston SM, Raab G and Freeman MR: BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 276: 30127-30132, 2001.
28. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H and Mekada E: Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727, 2004.
29. Yagi H, Miyamoto S, Tanaka Y, Sonoda K, Kobayashi H, Kishikawa T, Iwamoto R, Mekada E and Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer 92: 1737-1745, 2005.
30. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M and Mekada E: Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270: 1015-1019, 1995.
31. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E and Nakano H: Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cahceir. Clin Cancer Res 11: 4783-4792, 2005.
32. Yagi H, Yotsumoto F and Miyamoto S: Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 7: 3441-3451, 2008.
33. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C and Pironi F: CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 53: 1041-1048, 2004. (Pubitemid 39371748)
34. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E and Miyamoto S: Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 124: 1429-1439, 2009.
35. Sarup J, Jin P, Turin L, Bai X, Beryt M, Brdlik C, Higaki JN, Jorgensen B, Lau FW, Lindley P, Liu J, Ni I, Rozzelle J, Kumari R, Watson SA, Zhang J and Shepard HM: Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther 7: 3223-3236, 2008.
36. Jin P, Zhang J, Beryt M, Turin L, Brdlik C, Feng Y, Bai X, Liu J and Jorgensen B, Shepard HM: Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Mol Med 15: 11-20, 2009.